Dr. Niesvizky on Sequencing Therapies for Patients With Multiple Myeloma

Ruben Niesvizky, MD
Published: Friday, Aug 04, 2017



Ruben Niesvizky, MD, professor of medicine, Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medical College/NewYork-Presbyterian Hospital, discusses sequencing agents for patients with multiple myeloma.

Sequential therapy is part of the natural algorithms for the disease, Niesvizky explains. In the future, he says, he can foresee achieving minimal residual disease (MRD) negativity and hopefully offer patients disease-free and drug-free states. That will only be possible, however, once patients are randomized to receive treatment or not, depending on the MRD state, in clinical trials.

Moreover, researchers need to better define MRD, he adds. Imaging will be important and will be incorporated into that question.


Ruben Niesvizky, MD, professor of medicine, Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medical College/NewYork-Presbyterian Hospital, discusses sequencing agents for patients with multiple myeloma.

Sequential therapy is part of the natural algorithms for the disease, Niesvizky explains. In the future, he says, he can foresee achieving minimal residual disease (MRD) negativity and hopefully offer patients disease-free and drug-free states. That will only be possible, however, once patients are randomized to receive treatment or not, depending on the MRD state, in clinical trials.

Moreover, researchers need to better define MRD, he adds. Imaging will be important and will be incorporated into that question.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x